NASDAQ · Medical - Diagnostics & Research
CSTL (CSTL) Stock
$24.44
-0.99%
NASDAQ: CSTL
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
PR Newswire · Jul 14, 2026
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
PR Newswire · Jul 9, 2026
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
Exec Edge · Jul 1, 2026
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down
Simply Wall St. · Jun 26, 2026
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
PR Newswire · Jun 25, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held2.73%
Institutions Held92.43%
Institutions Float Held95.03%
Peer Comparison
About CSTL
CSTL is led by CEO Derek J. Maetzold, employs 784 people, headquartered in US, publicly traded since 2019.
CSTL stock trades at $24.44 with a market capitalization of $741.26M. The stock is valued at a price-to-earnings (P/E) ratio of -23.63, price-to-book of 1.26, price-to-sales of 1.81. Over the past 52 weeks the stock has ranged between $14.59 and $44.28, and currently trades 44.8% below its 52-week high.
On profitability, CSTL generates a return on equity (ROE) of -5.10%, return on capital employed of -9.13%, an operating margin of -12.50%, a net profit margin of -3.78%.